GLGC Gene Logic Inc. (MM)

Gene Logic Inc. (NASDAQ: GLGC) today released ASCENTA(R) System 2.0, a robust new version of its existing web-based product for gene and biomarker discovery and validation. Version 2.0 offers new gene expression information and progressive tools to help researchers identify key genes and biological pathways which possess distinctive expression characteristics and disease-related expression patterns. The latest ASCENTA System includes Gene Logic's: -- Marker/X(TM) Tool, a suite of new algorithms and visual tools to identify genes with distinctive expression behavior in humans -- Diff/X(TM) Summary Tables for enhanced ability to gain a quick and comprehensive view of target gene regulation -- PathwayPrioritizer(TM) Tool to obtain statistically ranked biological pathways regulated in altered biological states. The PathwayPrioritizer Tool also links to detailed gene regulation information -- New human gene expression information, including inflammation content for multiple sclerosis and inflammatory bowel disease, and central nervous system content for Parkinson's disease Dennis Rossi, senior vice president and general manager, Genomics for Gene Logic, said, "The ASCENTA System 2.0 provides our customers with a suite of new tools and functionalities that are unique in the marketplace. This new version is a necessary evolution to meet the complex and changing needs of our customers. Our goal is to furnish our customers with new tools to better understand the regulation of key biological pathways in human disease and quickly identify genes with unique and distinguishing expression patterns in human tissues. We envision that dynamic application of these new tools to our enhanced gene expression data will quicken the path to drug target, biomarker and pathway discovery." Gene Logic Overview Gene Logic aspires to be the most valued drug development solutions partner to the pharmaceutical industry. Gene Logic applies its broad and unique mix of technologies, talent and methodologies to work on behalf of its partners to enable pharmaceutical and biotechnology companies to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.